Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inner Mongolia Furui Medical Science Co FCF Margin % Chart
Inner Mongolia Furui Medical Science Co Annual Data
SZSE:300049 vs VRTX, REGN, RVMD: FCF Margin % Comparison
For the Biotechnology subindustry, Inner Mongolia Furui Medical Science Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inner Mongolia Furui Medical Science Co FCF Margin % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inner Mongolia Furui Medical Science Co (SZSE:300049) has a FCF Margin % of 13.48% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Inner Mongolia Furui Medical Science Co and its competitors. This is 33% above median its historical median of 10.11. According to the industry distribution chart, Inner Mongolia Furui Medical Science Co ranks #161 out of 956 companies in the Biotechnology industry, placing it in the top 16.8%.
Is Inner Mongolia Furui Medical Science Co's FCF Margin % too high?
Inner Mongolia Furui Medical Science Co's current FCF Margin % of 13.48% is 33% above median its 10-year median of 10.11. Based on the distribution chart, Inner Mongolia Furui Medical Science Co ranks #161 out of 956 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Inner Mongolia Furui Medical Science Co has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Inner Mongolia Furui Medical Science Co's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Inner Mongolia Furui Medical Science Co ranks #161 out of 956 companies for FCF Margin %. This places Inner Mongolia Furui Medical Science Co in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Inner Mongolia Furui Medical Science Co and its competitors. Inner Mongolia Furui Medical Science Co's current FCF Margin % is 13.48%, which is 33% above median its own 10-year median of 10.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inner Mongolia Furui Medical Science Co stock overvalued right now?
Based on GuruFocus' analysis, Inner Mongolia Furui Medical Science Co (SZSE:300049) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥65.97, compared to a current price of ¥43.94 — trading 33.4% below its estimated fair value. The current FCF Margin % is 13.48%, which is 33% above median its 10-year median of 10.11. Inner Mongolia Furui Medical Science Co's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Inner Mongolia Furui Medical Science Co (SZSE:300049), the current FCF Margin % is 13.48% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inner Mongolia Furui Medical Science Co (SZSE:300049) Overvalued in 2026?
Based on GuruFocus' analysis, Inner Mongolia Furui Medical Science Co stock appears to be undervalued.
The current stock price of ¥43.94 is trading 33.4% below its estimated GF Value™ of ¥65.97.
GuruFocus considers Inner Mongolia Furui Medical Science Co to be Significantly Undervalued.
Key valuation signals for SZSE:300049:
FCF Margin %: 13.48% (33% above median its 10-year median of 10.11)
GF Value™: ¥65.97 vs. price of ¥43.94 (33.4% below fair value)
No single metric tells the full story. See the SZSE:300049 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inner Mongolia Furui Medical Science Co Ltd is a China based medical service platform company. It provides disease diagnosis, drug treatment and chronic disease management centered on the liver disease field. The product portfolio of the company includes tablets, capsules, and plaster. In addition, the company is also engaged in providing health-care services.
81GF Score
Get the complete analysis for SZSE:300049
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:300049 has been successfully added to your 
